Get the Stockscreener App
7.63
1.17%
-0.09
After Hours:
7.68
0.05
+0.66%
Arvinas Inc stock is traded at $7.63, with a volume of 3.53M.
It is down -1.17% in the last 24 hours and up +16.31% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.72
Open:
$7.502
24h Volume:
3.53M
Relative Volume:
1.34
Market Cap:
$672.25M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.6338
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-17.16%
1M Performance:
+16.31%
6M Performance:
-71.64%
1Y Performance:
-76.75%
1-Day Range:
$7.33
$7.91
1-Week Range:
$6.23
$9.68
52-Week Range:
$5.935
$37.38
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.63 | 672.25M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas (ARVN) Price Target Adjustment by Citigroup | ARVN Stock News - GuruFocus
Where Arvinas Stands With Analysts - Benzinga
Citi cuts Arvinas stock price target to $9.50, keeps neutral rating - Investing.com Nigeria
Arvinas (ARVN) Sees Analyst Downgrade and Significant Price Target Cut | ARVN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, ... - Bluefield Daily Telegraph
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 21.0% in April - MarketBeat
ARVN: BMO Capital Maintains Rating While Lowering Price Target | ARVN Stock News - GuruFocus
Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results, Beats Estimates By $2.07 EPS - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Bought by ArrowMark Colorado Holdings LLC - MarketBeat
Arvinas (ARVN) Target Price Lowered by Citi Amid Pipeline Developments | ARVN Stock News - GuruFocus
Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21 - marketscreener.com
Arvinas (ARVN) Downgraded by Truist Amid Market Concerns | ARVN Stock News - GuruFocus
Arvinas stock rating cut, price target slashed to $11 at Truist - Investing.com Australia
Arvinas, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsARVN - ACCESS Newswire
Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case - Seeking Alpha
Piper Sandler Reiterates Overweight Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Price Target Cut to $16.00 by Analysts at Barclays - MarketBeat
HC Wainwright Cuts Arvinas (NASDAQ:ARVN) Price Target to $24.00 - MarketBeat
Arvinas (NASDAQ:ARVN) Lowered to Hold Rating by TD Cowen - MarketBeat
Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - Yahoo
Jefferies Financial Group Reaffirms "Hold" Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Boxer Capital Management LLC Makes New Investment in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsARVN - ACCESS Newswire
Arvinas, Inc. (NASDAQ:ARVN) Shares Bought by Barclays PLC - MarketBeat
Arvinas (ARVN) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Price T Rowe Associates Inc. MD Has $78.66 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Schonfeld Strategic Advisors LLC Has $12.58 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Renaissance Technologies LLC Lowers Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Brokerages Set Arvinas, Inc. (NASDAQ:ARVN) Price Target at $34.33 - MarketBeat
Arvinas, Inc. (ARVN) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Arvinas stock rating cut to hold at TD Cowen after trial cancellations - Investing.com India
Arvinas Earnings Call: Clinical Progress and Strategic Shifts - TipRanks
BTIG cuts Arvinas stock price target to $16 from $69 By Investing.com - Investing.com South Africa
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Arvinas (ARVN) Stock: Wells Fargo Lowers Price Target to $19 | ARVN Stock News - GuruFocus
Arvinas (ARVN) Faces Price Target Cut Amid Strategic Adjustments | ARVN Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Arvinas price target lowered to $10 from $20 at BMO Capital - TipRanks
Arvinas (ARVN) Target Price Lowered by Goldman Sachs | ARVN Stock News - GuruFocus
Guggenheim Maintains Buy Rating but Lowers Price Target for ARVN | ARVN Stock News - GuruFocus
Arvinas price target lowered to $14 from $24 at Piper Sandler - TipRanks
Arvinas price target lowered to $16 from $69 at BTIG - TipRanks
Arvinas (ARVN): Piper Sandler Adjusts Price Target Amid Reiteration of Rating | ARVN Stock News - GuruFocus
Barclays Analyst Lowers Price Target for Arvinas (ARVN) by 50% | ARVN Stock News - GuruFocus
Arvinas (ARVN) Price Target Reduced Following Strategic Restruct - GuruFocus
Arvinas Holding Company: Buy Rating Affirmed Amidst Promising Vepdeg Potential and Strong Financial Position - TipRanks
ARVN: HC Wainwright & Co. Adjusts Price Target While Maintaining Buy Rating | ARVN Stock News - GuruFocus
Here are 1 Main Capital Partners’ Views on Arvinas (ARVN) - Insider Monkey
Arvinas (ARVN) Price Target Reduced Following Strategic Restructuring | ARVN Stock News - GuruFocus
Jefferies Downgrades Arvinas (ARVN) with Significant Price Targe - GuruFocus
Arvinas (ARVN) Experiences Price Target Reduction Amid Developme - GuruFocus
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):